ENLV - Enlivex Therapeutics

-

$undefined

N/A

(N/A)

Enlivex Therapeutics NasdaqCM:ENLV Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

Location: 14 Einstein Street, Ness Ziona, 7403618, Israel | Website: https://www.enlivex.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-786.8K

Cash

23.5M

Avg Qtr Burn

-3.252M

Short % of Float

0.58%

Insider Ownership

4.61%

Institutional Own.

13.43%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Allocetra (Immunotherapy) Details
Treatment of organ failure associated with Sepsis, Organ failure

Phase 2b

Update

Phase 1/2

Data readout

Allocetra (Immunotherapy) Details
Osteoarthritis, Basal thumb osteoarthritis

Big Mover™

Susp. Mover™

Phase 1/2

Data readout

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued

Tovinontrine (IMR-687) Details
Beta thalessemia, Genetic disorder

Failed

Discontinued

Tovinontrine (IMR-687) Details
Sickle cell disease, Genetic disorder, Blood disorder

Failed

Discontinued

Allocetra (Immunotherapy) Details
COVID-19, Non-alcoholic steatohepatitis , Liver disease

Failed

Discontinued

Allocetra (Immunotherapy) Details
Bone marrow transplantation, Prevention of post-bone marrow transplantations complications

Failed

Discontinued